What AI says about MVASI

MVASI is a bevacizumab biosimilar approved for treating multiple cancers including metastatic colorectal, non-squamous non-small cell lung, recurrent glioblastoma, metastatic renal cell, cervical, and ovarian cancers. It is the only bevacizumab biosimilar that provides Amgen support and resources for patients and practices.